首页> 外文OA文献 >Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST)

【2h】

Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST)

机译：新型受体酪氨酸激酶靶向组合疗法用于伊替尼抗性胃肠肿瘤（GIST）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Daruka Mahadevan; Noah Theiss; Carla Morales; Amy E. Stejskal; Laurence S. Cooke; Min Zhu; Drew Kurtzman; Rachel Swart; Evan Ong; Wenqing Qi;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (c-KIT/PDGFR alpha) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) [J] . Lu Yanli, Mao Fei, Li Xiaokang, Journal of Medicinal Chemistry . 2017,第12期

机译：发现有效，选择性干细胞因子受体/血小板衍生的生长因子受体α（C-KIT / PDGFRα）双抑制剂，用于治疗伊马替尼抗性胃肠肿瘤肿瘤（GIST）
2. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials [J] . Lile Wu, Zhongqiang Zhang, Hongliang Yao, Drug Design, Development and Therapy . 2014,第1期

机译：第二代酪氨酸激酶抑制剂在伊马替尼耐药胃肠道间质瘤中的临床疗效：近期临床试验的荟萃分析
3. Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase [J] . Sommer G., Agosti V., Ehlers I., Proceedings of the National Academy of Sciences of the United States of America . 2003,第11期

机译：Kit受体酪氨酸激酶的靶向突变在小鼠模型中的胃肠道间质瘤
4. Receptor Tyrosine Kinases as Targets for Cancer Therapy Development [C] . Andreas Gschwind, Oliver M. Fischer, Axel Ullric Colloque me?decine et recherche . 2006

机译：受体酪氨酸激酶作为癌症治疗发展的靶标
5. Developing combinational immunotherapies targeting tumor receptor tyrosine kinases. [D] . Kawabe, Mayumi. 2009

机译：开发针对肿瘤受体酪氨酸激酶的组合免疫疗法。
6. Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST) [O] . Daruka Mahadevan, Noah Theiss, Carla Morales, 2015

机译：新型受体酪氨酸激酶靶向联合治疗伊马替尼耐药的胃肠道间质瘤（GIST）
7. Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells. [O] . Hiroyuki Sako, Kazumasa Fukuda, Yoshiro Saikawa, 2014

机译：酪氨酸激酶抑制剂尼罗替尼对胃肠道间质瘤（GIsT）和伊马替尼耐药GIsT细胞的抗肿瘤作用。
8. Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy: Part 2, Imatinib for Gastrointestinal Stromal Tumors (GIST) [R] . Abernethy, A. P., McCrory, D. C. 2005

机译：关于口服癌疗法对医疗保险受益人与目前报道疗法的相对疗效的报告：第2部分，伊马替尼治疗胃肠道间质瘤（GIsT）

Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST)

著录项

引文网络

相似文献

相关主题

期刊订阅